News
BLUE
7.65
-1.80%
-0.14
Looking Into bluebird bio's Return On Capital Employed
Benzinga · 1d ago
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
Benzinga · 1d ago
Bluebird Bio to Receive Much-Needed Cash From Fast Pass Sale
Bloomberg · 1d ago
BRIEF-Bluebird Bio Sells Priority Review Voucher For $102 Mln
Reuters · 1d ago
bluebird bio Sells Rare Pediatric Disease Priority Review Voucher For $102M
Benzinga · 1d ago
bluebird bio Sells Priority Review Voucher for $102 Million
SOMERVILLE, Mass., November 30, 2022--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $102 million.
Business Wire · 1d ago
FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
Benzinga · 11/23 13:12
Analyst Ratings for bluebird bio
Benzinga · 11/08 19:07
Expert Ratings for bluebird bio
Benzinga · 11/08 15:25
RBC Capital Maintains Sector Perform on bluebird bio, Lowers Price Target to $8
Benzinga · 11/08 12:16
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Benzinga · 11/08 10:00
--RBC Cuts Price Target on bluebird bio to $8 From $10, Maintains Sector Perform Rating, Speculative Risk Qualifier
--RBC Cuts Price Target on bluebird bio to $8 From $10, Maintains Sector Perform Rating, Speculative Risk Qualifier
MT Newswires · 11/08 08:31
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
Benzinga · 11/08 07:00
Recap: bluebird bio Q3 Earnings
Benzinga · 11/07 13:30
Bluebird Bio (BLUE) Reports Q3 Loss, Misses Revenue Estimates
Bluebird (BLUE) delivered earnings and revenue surprises of 28.13% and 96.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/07 13:25
bluebird bio GAAP EPS of -$0.94 beats by $0.24
Seekingalpha · 11/07 12:31
bluebird bio Q3 EPS $(0.94) Up From $(3.16) YoY
Benzinga · 11/07 12:15
BRIEF-Bluebird Bio Reports Third Quarter 2022 Financial Results
Reuters · 11/07 12:03
bluebird bio's Q3 Loss Narrows; Revenue Drops
bluebird bio's Q3 Loss Narrows; Revenue Drops
MT Newswires · 11/07 08:30
-- Earnings Flash (BLUE) BLUEBIRD BIO Posts Q3 Revenue $71,000
-- Earnings Flash (BLUE) BLUEBIRD BIO Posts Q3 Revenue $71,000
MT Newswires · 11/07 07:13
More
Webull provides a variety of real-time BLUE stock news. You can receive the latest news about Bluebird Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About BLUE
bluebird bio, Inc. is a biotechnology company. The Company is principally focused on researching, developing and commercializing gene therapies for genetic diseases. The Company’s gene therapy programs in genetic diseases include programs for B-thalassemia; LentiGlobin product candidate as a treatment for sickle cell disease (SCD), and elivaldogene autotemcel (eli-cel) as a treatment for cerebral adrenoleukodystrophy (CALD). It is using a lentiviral vector (LVV) platform, it custom designs each of its therapies to address the underlying cause of disease. The Company is developing lovotibeglogene autotemcel (lovo-cel) as a one-time treatment for patients with SCD, a genetic disease caused by a single mutation in the B-globin gene that leads to the production of abnormal sickle hemoglobin (HbS). The BLA for betibeglogene autotemcel (beti-cel) is for B-thalassemia in patients who receive regular red blood cell (RBC) transfusions.